To secure the antibody, I-Mab is paying $1.8 million upfront to buy Bridge Health, to be followed by noncontingent quarterly ...

The product candidates combine Byondis’ expertise in linker-drug (LD) technology, antibody-drug conjugation, targeted cytotoxic therapy, immunology, and monoclonal antibody (mAb) development.

Earlier, in January 2025, the FDA released a companion piece of draft guidance titled “Considerations for the Use of ...

For $1.8 million upfront and additional contingent and milestone payments, I-Mab gains full rights to givastomig's parental antibody.

The cell line development workflow makes it easy to screen thousands of clones at once, with in-depth characterization.

Dr. Scott Howell has a conflict of interest in relation to service on the Committee on Strategies to Better Align Investments in Innovations for Therapeutic Development with Disease Burden and Unmet ...

Quiet quitting, the Great Resignation, chronically low engagement numbers, increasing numbers of labor disputes, demands for equity and dignity in the workplace—business leaders have been warily ...